1. Home
  2. COOK vs ALXO Comparison

COOK vs ALXO Comparison

Compare COOK & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Traeger Inc.

COOK

Traeger Inc.

HOLD

Current Price

$73.83

Market Cap

201.0M

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$2.07

Market Cap

205.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
COOK
ALXO
Founded
1985
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Wholesale Distributors
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
201.0M
205.9M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
COOK
ALXO
Price
$73.83
$2.07
Analyst Decision
Hold
Strong Buy
Analyst Count
5
4
Target Price
$53.00
$3.50
AVG Volume (30 Days)
49.0K
1.9M
Earning Date
05-11-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
26.36
EPS
1.08
N/A
Revenue
$559,520,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$3.07
N/A
P/E Ratio
$68.36
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.44
52 Week High
$86.59
$2.66

Technical Indicators

Market Signals
Indicator
COOK
ALXO
Relative Strength Index (RSI) 56.53 61.34
Support Level $59.25 $1.99
Resistance Level $75.82 $2.27
Average True Range (ATR) 7.58 0.17
MACD -0.37 0.07
Stochastic Oscillator 49.14 79.10

Price Performance

Historical Comparison
COOK
ALXO

About COOK Traeger Inc.

Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: